Sibutramine Hydrochloride CAS106650-56-0

SibutramineHydrochlorideCAS106650-56-0 Weight loss drug White crystalline powder Slimming material Sibutramine

Introduction to drugs.

Drug name: Sibutramine hydrochloride,

Chemical name :N-{1-[1-(4-chlorophenyl) cyclobutyl] -3-methylbutyl}-N, N' -dimethylamine monohydrate hydrochloride,

Molecular formula :C17H26ClN? HCl? H2O,

Soluble in methanol melting point :193.0~195.0℃

Burning residue :≤0.1%

Heavy metal (Pb):≤10.0ppm

Thin plate chromatography (TLC): Only a single spot

Impurity :≤0.2%

Total impurity :≤0.4% Content :≥99.0%.

Drug nicknames: Trimei, Olina, Nometine Aolina, Reductil

Sibutramine hydrochloride,

Drug description: 10mg: capsule, the content is white or white powder. Tablet :10mg/ tablet.

Usage and dosage: Body mass index (BMI) calculation: weight (kg) divided by height (meters) square value (kg/m2). The recommended starting dose is 10mg once a day, taken in the morning alone or with food. If weight loss is insufficient, the dose can be adjusted to 15mg daily after 4 weeks. If the patient cannot tolerate 10mg dose, it can be reduced to 5mg. The dosage should be adjusted according to the patient's blood pressure and heart rate. Doses above 15mg/ day are not recommended.

Fold edit this paragraph drug action.

Fold sibutramine

Because of the low price of sibutramine, fenfluramine and other drugs, and do have a certain effect of food inhibition and weight loss, has been clever by some illegal businesses to add weight loss food profiteering. Sibutramine has been banned in many countries after it was linked to dozens of deaths in Germany, the United States and Italy. Experts warn that consumers who unknowingly take health food containing this ingredient can have serious consequences. (Some users also appeared some side effects, Sibuqu name will make endocrine disorders, have strong side effects on the skin, such as "fire" symptoms! Attention, please!)

SCOUT study(Sibutramine Cardiovascular Outcome Trial)

From December 2002, a large-scale Trial called SCOUT(Sibutramine Cardiovascular Outcome Trial) was initiated. A total of 9,800 obese and overweight patients took part in the study. The participants were all over 55 years old and had a history of heart disease and diabetes, but had not recently relapsed. The whole experiment lasted six years.

Sibutramine lost an average of only 2kg to 4kg more in the SCOUT group than in a placebo group. And it's not clear that the effect lasts after the drug is stopped. Sibutramine carries a serious but not fatal risk of cardiovascular disease, such as stroke and heart attack. The study led directly to the ban of Sibutramine in the European Union